Cilostazol
- Generic Name
- Cilostazol
- Drug Type
- Small Molecule
- Chemical Formula
- C20H27N5O2
- CAS Number
- 73963-72-1
- Unique Ingredient Identifier
- N7Z035406B
- Background
Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.
- Indication
Indicated for the alleviation of symptoms of intermittent claudication (pain in the legs that occurs with walking and disappears with rest).
- Associated Conditions
- Intermittent Claudication
The Phosphodiesterase 3 Inhibitor Cilostazol as an Adjunct to Conventional Therapy in Patients With Osteoarthritis
- Conditions
- Osteoarthritis
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Sadat City University
- Target Recruit Count
- 120
- Registration Number
- NCT04789837
- Locations
- 🇪🇬
Faculty of Pharmacy, Shibīn Al Kawm, Menoufia, Egypt
Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver Disease
- Conditions
- Fatty Liver, Nonalcoholic
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Sadat City University
- Target Recruit Count
- 120
- Registration Number
- NCT04761848
- Locations
- 🇪🇬
Faculty of Pharmacy, Shibīn Al Kawm, Menoufia, Egypt
Retina is a Marker for Cerebrovascular Heath
- Conditions
- Cerebral Small Vessel DiseasesCerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and LeukoencephalopathyCerebral MicrobleedingSporadic White Matter Disease
- Interventions
- First Posted Date
- 2021-02-15
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 100
- Registration Number
- NCT04753970
- Locations
- 🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States
The Effect of Anti-calcitonin Gene-related Peptide (CGRP) Receptor Antibodies on the Headache Inducing Properties of CGRP and Cilostazol in Migraine Patients
- Conditions
- Migraine Without AuraMigraine With AuraMigraine
- Interventions
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Danish Headache Center
- Target Recruit Count
- 72
- Registration Number
- NCT04452929
- Locations
- 🇩🇰
Danish Headache Center, Glostrup, Denmark
Cilostazol and Endothelial Progenitor Cell
- Conditions
- Myocardial Infarction, Acute
- Interventions
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2020-05-29
- Lead Sponsor
- Gyeongsang National University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04407312
Cilostazol and Nimodipine Combined Therapy After Aneurysmal Subarachnoid Hemorrhage (aSAH)
- Conditions
- Aneurysmal Subarachnoid Hemorrhage
- Interventions
- Other: Placebo
- First Posted Date
- 2019-11-01
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Ascension South East Michigan
- Target Recruit Count
- 19
- Registration Number
- NCT04148105
- Locations
- 🇺🇸
Ascension Providence Hospital, Southfield, Michigan, United States
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Sadat City University
- Target Recruit Count
- 80
- Registration Number
- NCT04069819
- Locations
- 🇪🇬
Faculty of Medicine, Shibīn Al Kawm, Egypt
Bioequivalence Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers
- Conditions
- Intermittent Claudication
- Interventions
- Drug: PMR 200 mg
- First Posted Date
- 2019-03-06
- Last Posted Date
- 2019-05-14
- Lead Sponsor
- Genovate Biotechnology Co., Ltd.,
- Target Recruit Count
- 28
- Registration Number
- NCT03864666
- Locations
- 🇺🇸
Bio-Kinetic Clinical Applications, LLC, Springfield, Missouri, United States
Oxford Haemodynamic Adaptation to Reduce Pulsatility Trial
- Conditions
- Small Vessel Cerebrovascular Disease
- Interventions
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 75
- Registration Number
- NCT03855332
- Locations
- 🇬🇧
University of Oxford, Oxford, Oxon, United Kingdom
Comparison of Two Different Antiplatelet Preparations for an Unruptured Intracranial Aneurysm
- Conditions
- Aneurysm, CerebralEndovascular Procedures
- Interventions
- First Posted Date
- 2018-07-10
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 198
- Registration Number
- NCT03581409
- Locations
- 🇰🇷
Seoul National Univeristy Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.